Cargando…

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26–45%; stage II: 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kris, Mark G., Mitsudomi, Tetsuya, Peters, Solange
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183392/ https://www.ncbi.nlm.nih.gov/pubmed/37197636 http://dx.doi.org/10.21037/tlcr-22-723

Ejemplares similares

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
por: Kobayashi, Yoshihisa, et al.
Publicado: (2016)

Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II–III
por: Kawaguchi, Yohei, et al.
Publicado: (2019)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
por: Facciolà, Alessio, et al.
Publicado: (2022)

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
por: Shalata, Walid, et al.
Publicado: (2021)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Alpha-D-glucan-based vaccine adjuvants: Current status and future perspectives
por: Patil, Veerupaxagouda, et al.
Publicado: (2022)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
por: Hu, Wenxian, et al.
Publicado: (2021)

Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma
por: Zou, Jiawei, et al.
Publicado: (2017)

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
por: Yao, Shuyang, et al.
Publicado: (2016)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
por: Siwak, Doris R., et al.
Publicado: (2010)

The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis
por: Li, Wei-Ping, et al.
Publicado: (2020)

Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma
por: Kondo, Yasuto, et al.
Publicado: (2022)

Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
por: Cho, Jang Ho, et al.
Publicado: (2017)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
por: Isaka, Tetsuya, et al.
Publicado: (2022)

Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study
por: Jazieh, Abdul Rahman, et al.
Publicado: (2022)

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
por: Khaddour, Karam, et al.
Publicado: (2021)

Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
por: Naldini, Luigi
Publicado: (2019)

Beyond N staging in colorectal cancer: Current approaches and future perspectives
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K‐ras mutation
por: Kaseda, Kaoru, et al.
Publicado: (2017)

Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I–III
por: Lino-Silva, Leonardo S., et al.
Publicado: (2020)

Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
por: Ye, Jing-Ren, et al.
Publicado: (2022)

Adjuvants to local anesthetics: Current understanding and future trends
por: Swain, Amlan, et al.
Publicado: (2017)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
por: Testori, Alessandro A. E., et al.
Publicado: (2020)

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer
por: Mizuuchi, Hiroshi, et al.
Publicado: (2016)

Current status and future directions in unresectable stage III non-small cell lung cancer
por: Arellano, Esperanza Arriola, et al.
Publicado: (2020)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
por: Majem, Margarita, et al.
Publicado: (2022)

New-age vaccine adjuvants, their development, and future perspective
por: Verma, Shailendra Kumar, et al.
Publicado: (2023)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Factors associated with the use of adjuvant radiation therapy in stage III melanoma
por: King, Amber L. O., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_olpqb6hfovv73vpc3colmp04hl